Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2041 to 2055 of 2187 results for guidelines

  1. Sleepio to treat insomnia and insomnia symptoms (HTG624)

    Evidence-based recommendations on Sleepio to treat insomnia and insomnia symptoms.

  2. RIDASCREEN tests for monitoring infliximab in inflammatory bowel disease (MIB109)

    NICE has developed a medtech innovation briefing (MIB) on RIDASCREEN tests for monitoring infliximab in inflammatory bowel disease .

  3. Fostamatinib for treating refractory chronic immune thrombocytopenia (TA835)

    Evidence-based recommendations on fostamatinib (Tavlesse) for chronic refractory chronic immune thrombocytopenia in adults.

  4. Spesolimab for treating generalised pustular psoriasis flares (TA1070)

    Evidence-based recommendations on spesolimab (Spevigo) for treating generalised pustular psoriasis flares in adults.

  5. Erdafitinib for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor (TA1062)

    Evidence-based recommendations on erdafitinib (Balversa) for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor in adults.

  6. Idiopathic sudden sensorineural hearing loss:- What is the most effective route of administration of steroids as a first-line treatment for idiopathic sudden sensorineural hearing loss?

    care provided to people with SSNHL and on our ability to develop robust guidelines and policy. Source guidance details Comes from...

  7. ThermoCool SmartTouch catheter for percutaneous radiofrequency ablation in atrial fibrillation (MIB61)

    NICE has developed a medtech innovation briefing (MIB) on the ThermoCool SmartTouch catheter for percutaneous radiofrequency ablation in atrial fibrillation

  8. Ekso exoskeleton for rehabilitation in people with neurological weakness or paralysis (MIB93)

    NICE has developed a medtech innovation briefing (MIB) on the Ekso exoskeleton for rehabilitation in people with neurological weakness or paralysis .

  9. Artificial intelligence (AI) technologies for assessing and triaging skin lesions referred to the urgent suspected skin cancer pathway: early value assessment (HTG746)

    Early value assessment (EVA) guidance on artificial intelligence (AI) technologies for assessing and triaging skin lesions referred to the urgent suspected skin cancer pathway.

  10. Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer (TA816)

    Evidence-based recommendations on alpelisib (Piqray) with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated, locally advanced or metastatic breast cancer in adults.

  11. The Epidrum for aiding access to the epidural space (MIB23)

    NICE has developed a medtech innovation briefing (MIB) on the Epidrum for aiding access to the epidural space

  12. Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations (TA952)

    Evidence-based recommendations on talazoparib (Talzenna) for HER2-negative, locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations in adults.

  13. Fruquintinib for previously treated metastatic colorectal cancer (TA1079)

    Evidence-based recommendations on fruquintinib (Fruzaqla) for previously treated metastatic colorectal cancer in adults.

  14. superDimension Navigation System to help diagnostic sampling of peripheral lung lesions (MIB194)

    NICE has developed a medtech innovation briefing (MIB) on superDimension Navigation System to help diagnostic sampling of peripheral lung lesions .

  15. Leniolisib for treating activated phosphoinositide 3-kinase delta syndrome in people 12 years and over (HST33)

    Evidence-based recommendations on leniolisib (Joenja) for treating activated phosphoinositide 3-kinase delta syndrome in people 12 years and over.